Edition:
United Kingdom

Nabriva Therapeutics PLC (NBRV.OQ)

NBRV.OQ on NASDAQ Stock Exchange Global Select Market

2.56USD
6:09pm BST
Change (% chg)

$0.02 (+0.79%)
Prev Close
$2.54
Open
$2.57
Day's High
$2.57
Day's Low
$2.54
Volume
39,146
Avg. Vol
118,089
52-wk High
$8.56
52-wk Low
$2.34

Latest Key Developments (Source: Significant Developments)

Nabriva Therapeutics Q2 Loss Per Share $0.44
Thursday, 9 Aug 2018 

Nabriva Therapeutics PLC ::NABRIVA THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q2 LOSS PER SHARE $0.44.Q2 EARNINGS PER SHARE VIEW $-0.48 -- THOMSON REUTERS I/B/E/S.CO PREPARING FOR POTENTIAL COMMERCIALIZATION OF 2 FIRST-IN-CLASS ANTIBIOTICS, IN UNITED STATES IN 2019.QTRLY TOTAL REVENUE $847,000 VERSUS $1.1 MILLION.  Full Article

Nabriva Therapeutics Strengthens Antibiotics Leadership Position With Acquisition Of Zavante Therapeutics
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Nabriva Therapeutics PLC ::NABRIVA THERAPEUTICS STRENGTHENS ANTIBIOTICS LEADERSHIP POSITION WITH ACQUISITION OF ZAVANTE THERAPEUTICS.NABRIVA THERAPEUTICS PLC - ON TRACK TO FILE NEW DRUG APPLICATIONS FOR LEFAMULIN AND CONTEPO IN Q4.NABRIVA THERAPEUTICS PLC - TED SCHROEDER APPOINTED AS NABRIVA'S CEO.NABRIVA THERAPEUTICS PLC - COLIN BROOM TO CONTINUE TO SERVE ON NABRIVA BOARD.NABRIVA THERAPEUTICS - ACQUIRED ZAVANTE THERAPEUTICS FOR UPFRONT CONSIDERATION OF ABOUT 8.2 MILLION OF CO'S ORDINARY SHARES.NABRIVA THERAPEUTICS - ZAVANTE THERAPEUTICS' FORMER STOCKHOLDERS ELIGIBLE TO RECEIVE UP TO $97.5 MILLION UPON ACHIEVEMENT OF CERTAIN MILESTONES.NABRIVA THERAPEUTICS - SCHROEDER TO SUCCEED BROOM AS CEO.  Full Article

Nabriva Therapeutics And Roivant Sciences Enter Into License Agreement
Tuesday, 27 Mar 2018 

March 27 (Reuters) - Nabriva Therapeutics Plc ::NABRIVA THERAPEUTICS AND ROIVANT SCIENCES ENTER INTO LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE LEFAMULIN IN GREATER CHINA.NABRIVA THERAPEUTICS - LEFAMULIN HAS COMPLETED PHASE 3 TRIAL FOR TREATMENT OF ADULTS WITH MODERATE TO SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA.NABRIVA THERAPEUTICS PLC - TOPLINE DATA FROM A SECOND LEFAMULIN INTERNATIONAL PHASE 3 CLINICAL TRIAL ARE EXPECTED IN SPRING OF 2018.  Full Article

Nabriva Therapeutics Announces Completion Of Enrollment In Leap 2, A Phase 3 Clinical Trial Evaluating Oral Lefamulin
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Nabriva Therapeutics Plc ::NABRIVA THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN LEAP 2, A PHASE 3 CLINICAL TRIAL EVALUATING ORAL LEFAMULIN FOR THE TREATMENT OF COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA IN ADULTS.NABRIVA THERAPEUTICS PLC - ‍ANTICIPATES TOPLINE CLINICAL RESULTS FROM LEAP 2 TO BE AVAILABLE IN SPRING OF 2018​.  Full Article

Nabriva Therapeutics reports Q3 loss per share $0.79
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Nabriva Therapeutics Plc :Nabriva Therapeutics reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.79.Q3 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S.Nabriva - On track to complete patient enrollment for second phase 3 trial, leap 2, before year end 2017, & expects topline results in spring 2018​.Nabriva Therapeutics Plc - ‍$112.7 million cash and investments as of September 30, 2017​.Nabriva Therapeutics Plc - ‍Cash balance is expected to fund operations into Q4 of 2018​.  Full Article

UPDATE 3-Nabriva shares tumble as safety worries plague pneumonia drug

* Co to seek approval for drug in Q4 2018 (Adds analyst quote, updates stock price)